GlaxoSmithKline hustles the 7th PD-1 past the finish line with Jemperli. But how big will uptake be?
Everything came up sevens for GlaxoSmithKline on Thursday as the pharma notched the seventh PD-1 approval seven years after the first such drugs were OK’ed in Keytruda and Opdivo. But will it bring GSK good fortune?
The FDA granted accelerated approval to dostarlimab, to be branded Jemperli, to treat recurrent or advanced endometrial cancer in a specific subset of patients following platinum-based chemo. It’s a drug that came to GSK through its buyout of Tesaro, which it snapped up for $5.1 billion back in December 2018.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 104,600+ biopharma pros reading Endpoints daily — and it's free.